dipyridamole has been researched along with eptifibatide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Butenas, S; Cawthern, KM; DiLorenzo, ME; Lock, JB; Mann, KG; van't Veer, C | 1 |
| Lecompte, T | 1 |
| Azevedo, R; Beierlein, W; Dietz, K; Straub, A; Wendel, HP; Ziemer, G | 1 |
| Abraham, J; Jones, PA; Kramer, J; Teven, CM | 1 |
| Fontana, P | 1 |
3 review(s) available for dipyridamole and eptifibatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyridamole; Drug Monitoring; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Membrane Proteins; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thrombosis; Thromboxanes; Ticlopidine | 2002 |
[Update on antithrombotic treatments in arterial diseases].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
3 other study(ies) available for dipyridamole and eptifibatide
| Article | Year |
|---|---|
Antiplatelet agents in tissue factor-induced blood coagulation.
Topics: Abciximab; Adult; Alprostadil; Animals; Antibodies, Monoclonal; Antithrombin III; Aspirin; Blood Coagulation; Dipyridamole; Eptifibatide; Fibrinopeptide A; Humans; Immunoglobulin Fab Fragments; Mice; Osteonectin; Partial Thromboplastin Time; Peptide Hydrolases; Peptides; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Prothrombin Time; Receptors, Thrombin; Thromboplastin | 2001 |
Tirofiban (Aggrastat) protects platelets and decreases platelet-granulocyte binding in an extracorporeal circulation model.
Topics: Aprotinin; Binding, Competitive; Biomarkers; Blood Platelets; Dipyridamole; Eptifibatide; Extracorporeal Circulation; Flow Cytometry; Granulocytes; Humans; Male; Milrinone; P-Selectin; Peptides; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Tirofiban; Tyrosine | 2006 |
Role of antiplatelets in carotid artery stenting.
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Stents; Stroke; Ticlopidine | 2007 |